GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (STU:4E2) » Definitions » Cash Flow for Lease Financing

Relmada Therapeutics (STU:4E2) Cash Flow for Lease Financing : €0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Relmada Therapeutics Cash Flow for Lease Financing?

Relmada Therapeutics's Cash Flow for Lease Financing for the three months ended in Mar. 2024 was €0.00 Mil. Relmada Therapeutics's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil.

Compared with last quarter (€0.00 Mil in Dec. 2023 ), Relmada Therapeutics's Cash Flow for Lease Financing remained the same in Mar. 2024 (€0.00 Mil).

Relmada Therapeutics Cash Flow for Lease Financing Historical Data

The historical data trend for Relmada Therapeutics's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relmada Therapeutics Cash Flow for Lease Financing Chart

Relmada Therapeutics Annual Data
Trend Aug13 Jun15 Jun16 Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23
Cash Flow for Lease Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Relmada Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow for Lease Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Relmada Therapeutics Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.


Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Relmada Therapeutics Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of Relmada Therapeutics's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Relmada Therapeutics (STU:4E2) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (STU:4E2) » Definitions » Cash Flow for Lease Financing
Comparable Companies
HOWL MIRO ALDX NYMXF HRTX ADVM OCGN NKTR SGMO BDTX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
RLMD:USA
Address
2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134
Website
https://www.relmada.com
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Relmada Therapeutics (STU:4E2) Headlines

No Headlines